This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Nov 20;371(21):2042.

doi: 10.1056/NEJMc1411443.

Donor activating KIR2DS1 in leukemia

Jeffrey M Venstrom¹, Bo Dupont, Katharine C Hsu, Gianfranco Pittari, Ted A Gooley, Joseph H Chewning, Stephen Spellman, Michael Haagenson, Meighan M Gallagher, Mari Malkki, Effie Petersdorf

Affiliations

PMID: 25409391
DOI: 10.1056/NEJMc1411443

Comment

Donor activating KIR2DS1 in leukemia

Jeffrey M Venstrom et al. N Engl J Med. 2014.

. 2014 Nov 20;371(21):2042.

doi: 10.1056/NEJMc1411443.

Authors

Jeffrey M Venstrom¹, Bo Dupont, Katharine C Hsu, Gianfranco Pittari, Ted A Gooley, Joseph H Chewning, Stephen Spellman, Michael Haagenson, Meighan M Gallagher, Mari Malkki, Effie Petersdorf

Affiliation

¹ University of California, San Francisco, San Francisco, CA.

PMID: 25409391
DOI: 10.1056/NEJMc1411443

No abstract available

PubMed Disclaimer

Comment on

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. Venstrom JM, et al. N Engl J Med. 2012 Aug 30;367(9):805-16. doi: 10.1056/NEJMoa1200503. N Engl J Med. 2012. PMID: 22931314 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information